Provided by Tiger Trade Technology Pte. Ltd.

Vivani Medical, Inc.

1.18
+0.01000.85%
Post-market: 1.180.00000.00%16:10 EST
Volume:118.70K
Turnover:141.32K
Market Cap:95.82M
PE:-2.67
High:1.22
Open:1.18
Low:1.17
Close:1.17
52wk High:1.92
52wk Low:0.9054
Shares:81.21M
Float Shares:36.07M
Volume Ratio:0.43
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4418
EPS(LYR):-0.4272
ROE:-265.02%
ROA:-50.05%
PB:73.20
PE(LYR):-2.76

Loading ...

Cortigent Reports Promising Six-Year Results for Orion Visual Prosthesis

Reuters
·
Jan 29

Vivani Medical Director and 10% Owner Gregg Williams Reports Acquisition of Common Shares

Reuters
·
Jan 28

Vivani Medical, Inc. Announces Closing of Common Stock Offering

THOMSON REUTERS
·
Jan 28

BRIEF-Vivani Medical Announces Pricing Of Common Stock Offering At $1.48 Per Share

Reuters
·
Jan 26

Vivani Medical Inc - Prices Direct Offering of 1,689,200 Shares at $1.48

THOMSON REUTERS
·
Jan 26

Vivani subsidiary to present poster on Orion Visual Cortical Prosthesis System

TIPRANKS
·
Jan 22

Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026

GlobeNewswire
·
Jan 22

Director and 10% Owner Gregg Williams Reports Acquisition of Vivani Medical Inc. Common Shares

Reuters
·
Jan 20

Vivani Medical Director Aaron Mendelsohn Reports Acquisition of Common Shares

Reuters
·
Dec 31, 2025

Director and 10% Owner Gregg Williams Acquires Common Shares of Vivani Medical Inc

Reuters
·
Dec 16, 2025

Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management

Reuters
·
Nov 25, 2025

Vivani Medical Q3 Net Income USD -6.53 Million

Reuters
·
Nov 20, 2025

Director and 10% Owner Gregg Williams Reports Acquisition of Vivani Medical Inc. Common Shares

Reuters
·
Nov 17, 2025

Vivani Medical reports wider Q3 net loss

Reuters
·
Nov 13, 2025

Vivani Medical Q3 EPS $(0.11), Inline

Benzinga
·
Nov 13, 2025

BRIEF-Vivani Medical Q3 Net Income USD -6.53 Million

Reuters
·
Nov 13, 2025

Vivani Medical Q3 Operating Expenses USD 6.725 Million

THOMSON REUTERS
·
Nov 13, 2025

Vivani Medical : Anticipates Initiating Clinical Development of Semaglutide Implant, Npm-139 in 2026

THOMSON REUTERS
·
Nov 13, 2025

Vivani Medical Q3 Income From Operations USD -6.725 Million

THOMSON REUTERS
·
Nov 13, 2025

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

THOMSON REUTERS
·
Nov 13, 2025